Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014448 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Kathrin Tomasek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology and Microtechnology, School of Life Sciences (SV), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Uropathogenic Escherichia coli, Lysosomes, Urinary Bladder, Urinary Tract Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesbehörden der Schweizerischen Eidgenossenschaft, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, IBSA Foundation.
Abstract (Originalsprache)
Recurrent urinary tract infections (UTIs) are a major clinical burden, driven in part by the ability of uropathogenic Escherichia coli (UPEC) to establish intracellular niches within the bladder epithelium, where bacteria withstand antibiotics and host defenses. The oral bacterial lysate OM-89 (Uro-Vaxom), a clinically approved and globally used therapy for the prevention and management of recurrent UTIs for several decades, reduces recurrence rates, but its cellular mechanisms of action remain incompletely understood. Here, we demonstrate that OM-89 strengthens antimicrobial defenses in bladder epithelial cells and, in combination with antibiotic therapy, limits post-antibiotic bacterial regrowth in epithelial infection models. OM-89 promotes lysosomal acidification and increases lysosomal protease activity in bladder organoids and differentiated epithelial monolayers, thereby directing intracellular UPEC toward degradative compartments. In parallel, OM-89 enhances intracellular accumulation of multiple antibiotic classes. These effects are conserved across distinct UPEC strains and in both murine and human epithelial models. Our findings demonstrate that bladder epithelial antimicrobial pathways can be pharmacologically reinforced to influence treatment outcomes by enhancing intracellular bacterial clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiology and Microtechnology, School of Life Sciences (SV), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
- Bioinformatics Competence Centre, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
- OM Pharma Ltd., Meyrin/Geneva, Switzerland.
ORCID-Profile: Kathrin Tomasek, Kristina Skurvydaite, Gauri Paduthol, Valentin Borgeat, Mario Romani
Förderung
- Bundesbehörden der Schweizerischen Eidgenossenschaft
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- IBSA Foundation
- Fondation Leenaards
- OM Pharma
Zitieren
APA
Tomasek, K., Skurvydaite, K., Paduthol, G., Burns, A. M., Schlunke, L., Borgeat, V., Pasquali, C., Romani, M., & McKinney, J. D. (2026). Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014448
Vancouver
Tomasek K, Skurvydaite K, Paduthol G, Burns AM, Schlunke L, Borgeat V, et al. Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014448
BibTeX
@article{Tomasek2026,
author = {Tomasek, Kathrin and Skurvydaite, Kristina and Paduthol, Gauri and Burns, Allison M and Schlunke, Léa and Borgeat, Valentin and Pasquali, Christian and Romani, Mario and McKinney, John D},
title = {Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014448}
}
EUVIMED